녹십자

006280KOSPI의약품 제조업

49.5 / 100

Reference Date: 2026-07-24

Financial Score12.0 / 40

News Sentiment20.5 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Slightly down 1.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

LG Chem is a pharmaceutical company specializing in blood products and vaccines, with 2025 consolidated sales reaching 19.9 trillion won, a 18.54% increase from the previous year. Key products include ALYGLO, successfully launched in the U.S. market, the WHO-certified chickenpox vaccine 'BariCella', and the hemophilia treatment 'Greenjin E' approved in China. The company is focused on global expansion through strategic products and innovation.

Number of Employees

2,351people

Average Salary

73.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.234.0Point

PBR

1.03Industry Average 0.812.5Point

Higher than industry avg (caution)

ROE

-2.07Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

30.91Industry Average 12.430.0Point

2.5x industry avg (risky)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲10.9% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲54.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -2.1% (declining, 3yr)

Detailed News Sentiment

38 totalPositive 35Neutral 2Negative 1Average Sentiment Score 82.1

Positive
GC녹십자 '알리글로' 앞세워 희귀질환·CGT로 영토 확장
GC녹십자의 '알리글로' 성공적인 미국 시장 진출로 인해 희귀질환 및 첨단 치료제 분야로의 사업 확장이 가속화되어 긍정적 전망을 보임.
Neutral
GC녹십자의료재단, 이종욱 펠로우십 프로그램 전문가 과정 환영식
GC녹십자의료재단의 전문가 연수 환영식이 열렸으나, 녹십자 주식에 직접적인 영향은 미미해 보입니다.
Positive
[단독] GC녹십자, 국산 mRNA 백신 첫 2상 도전…이번 주 IND...
GC녹십자가 국산 mRNA 백신의 첫 번째 후기 임상 진입을 추진하며, 기업의 혁신적인 연구 개발 능력을 인정받아 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (8%, downtrend)

Current 123,100Won52-week high 180,30052-week low 117,900

1-month return3.0Point

1m -1.52% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral신규시설투자등2026-07-16
Neutral[기재정정]주요사항보고서(타법인주식및출자증권양도결정)2026-07-10
Neutral[기재정정]주요사항보고서(타법인주식및출자증권양도결정)2026-07-09
Neutral주식등의대량보유상황보고서(약식)2026-07-01
Neutral최대주주등소유주식변동신고서2026-07-01